Aspirin for COVID-19: real-time meta-analysis of 79 studies (Version 70)

Significantly lower risk is seen for mortality and progression. 28 studies from 26 independent teams in 11 countries show significant benefit.

Meta-analysis using the most serious outcome reported shows 8% [2‑13%] lower risk. Early treatment is more effective than late treatment.

Control Aspirin

Studies to date do not show a significant benefit for mechanical ventilation and ICU admission. Benefit may be more likely without coadministered anticoagulants. The RECOVERY RCT shows 4% [-4‑11%] lower mortality for all patients, however when restricting to non-LMWH patients there was 17% [-4‑34%] improvement, comparable with the mortality results of all studies, 8% [2‑14%], and the 16% improvement in the REMAP-CAP RCT.

No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. All data and sources to reproduce this analysis are in the appendix.

4 other meta-analyses show significant improvements with aspirin for mortality1-3, mechanical ventilation1, and progression4.

4 meta-analyses show significant improvements with aspirin for mortality1-3, mechanical ventilation1, and progression4.